Market News (Page 1) - TendieTensor

Market News Page 1 of 280 • 6,996 articles

AOP Health’s Rapiblyk™ Now Accessible via Leading US Healthcare Improvement Companies

GlobeNewswire Inc. • Not Specified

AOP Health’s Rapiblyk™ Now Accessible via Leading US Healthcare Improvement Companies

01/12/2026 09:00 AM • AOP Health US announced expanded distribution of Rapiblyk™ (landiolol), an FDA-approved ultra-short-acting beta-blocker for treating rapid heart rates in critical care settings. The drug is now available through four major pharmaceutical wholesalers: Cardinal, Cencora Specialty Distribution, McKesson Corporation, and Morris & Dickson, enhancing accessibility for hospitals and health systems nationwide.

SHOP - Mentioned in context of beta-testing Managed Markets flow without detailed performance information
CAH - Cardinal is mentioned as one of four distribution partners for Rapiblyk, representing routine business expansion but without specific financial impact or strategic significance disclosed in the article.

#Rapiblyk #landiolol #beta-blocker #supraventricular tachycardia #atrial fibrillation #critical care #pharmaceutical distribution #FDA approval

Grocery Outlet Enters Sixteenth State with Store Opening in Virginia

GlobeNewswire Inc. • Na

Grocery Outlet Enters Sixteenth State with Store Opening in Virginia

01/12/2026 09:00 AM • Grocery Outlet announced its official entrance into Virginia with the opening of its first store in Falls Church on February 12, 2026. The expansion marks a key milestone in the company's long-term growth strategy, with plans for additional openings across the state. The retailer offers products at 40-70% below conventional retail prices.

TPR - Noted as a new partner in UK and Europe without specific performance context
GO - The company is executing its disciplined growth strategy by entering a new state market (Virginia), expanding its footprint to over 560 stores nationwide. The announcement demonstrates operational progress and market expansion momentum, which are positive indicators for investor confidence and future revenue growth.

#store expansion #Virginia market entry #extreme value retail #growth strategy #discount grocery #Falls Church opening

SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025

GlobeNewswire Inc. • Na

SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025

01/12/2026 09:00 AM • SI-BONE announced preliminary Q4 2025 revenue of $56.2-$56.3 million (~15% growth) and full year 2025 revenue of $200.8-$200.9 million (~20% growth). The company reported ~1,640 active U.S. physicians (18% increase) and cash equivalents of ~$147.7 million with net cash generation of ~$2.0 million in Q4. Final audited results will be provided in late February 2026.

SIBN - The company demonstrated strong financial performance with 20% full-year revenue growth, 21% U.S. revenue growth, 18% physician growth, and positive cash generation. These metrics indicate healthy business expansion and market adoption of their procedural solutions.

#medical device #revenue growth #SI joint fusion #spinal deformity #pelvic trauma #physician adoption #cash generation #additive manufacturing

Channelscaler More than Doubles Year-Over-Year Pipeline Growth for Partners in 2025

GlobeNewswire Inc. • Not Specified

Channelscaler More than Doubles Year-Over-Year Pipeline Growth for Partners in 2025

01/12/2026 09:00 AM • Channelscaler, a partner relationship management platform formed from the 2024 merger of Allbound and Channel Mechanics, announced significant growth in 2025 including expanded leadership team appointments, recognition as a market leader in IDC's PRM software assessment, and new AI-driven tools for partner program automation. The company reported partners achieving up to 200% year-over-year pipeline growth.

CCL - Strong post-pandemic recovery, record bookings, reducing debt, improving credit ratings, and trading at low P/E ratio of less than 14
SAP - SAP is mentioned only as a customer using Channelscaler's platform; no specific information about SAP's performance or sentiment drivers is provided in the article.

#partner relationship management #AI innovation #leadership expansion #SaaS growth #channel partner ecosystem #market recognition #platform automation

Distalmotion Secures Strategic Investment to Advance ASC Expansion of the DEXTER® Robotic Surgery System

GlobeNewswire Inc. • Not Specified

Distalmotion Secures Strategic Investment to Advance ASC Expansion of the DEXTER® Robotic Surgery System

01/12/2026 09:00 AM • Distalmotion announced a strategic investment from Johnson & Johnson's venture capital arm (JJDC) to advance expansion of its DEXTER robotic surgery system in ambulatory surgery centers (ASCs). This follows the company's $150M Series G funding round in 2025. DEXTER, designed specifically for outpatient settings, has been cleared in the US for hernia repair, cholecystectomy, and benign hysterectomy procedures, with over 3,000 patients treated to date.

JNJ - Strategic investment in Distalmotion through JJDC demonstrates J&J's commitment to robotic surgery innovation and positioning in the growing outpatient surgery market, indicating confidence in the DEXTER platform's potential.

#robotic surgery #ambulatory surgery centers #DEXTER system #venture capital investment #minimally invasive surgery #medical technology #outpatient care

InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)

GlobeNewswire Inc. • Inspiremd, Inc.

InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)

01/12/2026 09:00 AM • InspireMD announced that its C-GUARDIANS pivotal trial results have been published in JACC, demonstrating that the CGuard® Prime Carotid Stent System achieved the lowest 30-day and 1-year major adverse event rates in carotid stenting studies, with a 30-day DSMI rate of 0.95% and 1-year ipsilateral stroke rate of 1.93%. The trial enrolled 316 patients including 25% symptomatic cases, showing strong safety and efficacy data for carotid artery stenosis treatment.

STZ - Down 40% in 2025 but with significant analyst price target upside, low forward earnings multiple, and diverse beverage portfolio
NSPR - The company announced positive pivotal trial results published in a top-tier medical journal (JACC), demonstrating superior safety outcomes (lowest event rates in the industry) for its flagship product CGuard® Prime. The publication in a prestigious journal and achievement of primary endpoints with historically low complication rates represent significant validation and should support future adoption and revenue growth.

#carotid stenting #CGuard Prime #clinical trial results #stroke prevention #FDA approval #medical device #interventional cardiology

Oriental Culture Holding LTD Announces Special Cash Dividend Plan to Reward Shareholders on Fifth Anniversary of Listing

Benzinga • Prnewswire

Oriental Culture Holding LTD Announces Special Cash Dividend Plan to Reward Shareholders on Fifth Anniversary of Listing

01/12/2026 08:55 AM • Oriental Culture Holding (NASDAQ: OCG) announced a special cash dividend of $0.05 per share to celebrate its fifth anniversary of listing on Nasdaq. The dividend will be paid on February 9, 2026, to shareholders of record as of January 22, 2026. CEO Shao Yi stated the company is returning accumulated cash reserves to shareholders as a reward for their long-term support and to foster long-term value creation.

OCG - The announcement of a special cash dividend demonstrates financial strength and management's commitment to returning value to shareholders. The dividend payment indicates the company has sufficient cash reserves after funding operations, which is a positive signal of financial health and confidence in the business.

#special cash dividend #fifth anniversary #shareholder reward #Nasdaq listing #cash reserves

LightPath Technologies to Participate in the 28th Annual Needham Growth Conference on January 15, 2026

Benzinga • Prnewswire

LightPath Technologies to Participate in the 28th Annual Needham Growth Conference on January 15, 2026

01/12/2026 08:31 AM • LightPath Technologies (NASDAQ:LPTH) announced it will participate in the 28th Annual Needham Growth Conference on January 15, 2026, hosting one-on-one virtual meetings with institutional investors. The company highlighted its strengthened balance sheet following a recent financing and plans to discuss its defense and commercial optics platforms and strategic priorities.

LPTH - The company is actively engaging with institutional investors at a major growth conference, recently completed successful financing, and management expressed confidence in advancing strategic priorities and creating shareholder value. The tone is optimistic about market opportunities and the company's strengthened financial position.

#LightPath Technologies #Needham Growth Conference #optics and imaging systems #defense applications #commercial applications #investor meetings #balance sheet #infrared optical systems

Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (BlackRock, Inc.)

GlobeNewswire Inc. • Orion Corporation

Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (BlackRock, Inc.)

01/12/2026 08:00 AM • BlackRock, Inc. and its funds have exceeded the 5% ownership threshold in Orion Corporation, reaching a combined 5.01% stake as of January 9, 2026. The holding consists of 4.97% in direct shares (7,014,577 shares) and 0.04% through financial instruments including American Depositary Receipts and borrowed securities.

NSRGY - Mentioned as the seller of the infant formula plant and brand rights, with no direct negative implications in the lawsuit
BLK - The disclosure is a regulatory announcement of BlackRock crossing the 5% ownership threshold in Orion. This is a factual reporting of shareholding changes with no inherent positive or negative implications. It represents a significant investment position but does not indicate strategic intent or market impact.

#major shareholder disclosure #ownership threshold #BlackRock #Orion Corporation #5% stake #financial instruments #Securities Market Act

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences

GlobeNewswire Inc. • Na

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences

01/12/2026 08:00 AM • MDxHealth reported preliminary 2025 revenues of $109 million (21% YoY growth) with Q4 revenues of $30.5 million (23% YoY growth). The company issued 2026 revenue guidance of $137-140 million (26-28% growth) and expects to achieve a 10% adjusted EBITDA margin run rate by year-end 2026. MDxHealth amended its earnout obligations with Exact Sciences, deferring payments to 2026-2028 and issuing 3 million warrant shares at $5.265 per share.

EXAS - Exact Sciences benefited from earnout amendment deferring payments and receiving 3 million warrant shares, providing liquidity relief to MDxHealth. The amendment is mutually beneficial but represents a restructuring of original acquisition terms rather than new positive developments.

#precision diagnostics #prostate cancer testing #revenue growth #2026 guidance #earnout amendment #liquid-based units #tissue-based units #EBITDA margin #GPS test #ExoDx

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

GlobeNewswire Inc. • Orion Corporation Communications

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

01/12/2026 08:00 AM • BlackRock, Inc. and its funds have crossed the 5% ownership threshold in Orion Corporation as of January 9, 2026, holding 5.01% of total shares and voting rights (7,014,577 direct shares plus 57,180 shares through financial instruments). This disclosure was made under Chapter 9, Section 10 of the Securities Market Act.

BLK - The disclosure is a factual regulatory announcement of BlackRock crossing the 5% ownership threshold in Orion. While this indicates significant investment interest, the announcement itself is neutral in tone and is a standard regulatory filing with no indication of positive or negative implications for either party.

#major shareholder disclosure #5% threshold #ownership stake #BlackRock #Orion Corporation #Securities Market Act #voting rights

U.S. Mental Health Treatment Market Report and Directory 2026, Profiles of Acadia, Universal Health Services, Lyra Health, Spring Health, Headspace, Calm, Talkspace, BetterHelp, Carelon

GlobeNewswire Inc. • Marketdata Llc

U.S. Mental Health Treatment Market Report and Directory 2026, Profiles of Acadia, Universal Health Services, Lyra Health, Spring Health, Headspace, Calm, Talkspace, BetterHelp, Carelon

01/12/2026 07:59 AM • The U.S. mental health treatment market is valued at $118 billion and is projected to grow significantly through 2030, driven by increased awareness, technology integration, and rising mental illness prevalence affecting 61 million Americans. The sector faces challenges including a shortage of mental health professionals and access gaps, while teletherapy and mental health apps have created a $2 billion market segment. Major players include facility operators like Acadia Healthcare and Universal Health Services, alongside digital platforms such as Lyra Health, Spring Health, Headspace, Calm, Talkspace, and BetterHelp.

ACHC - Identified as a major industry leader in facility operations with strong market position in the growing $118 billion mental health treatment market

#mental health market #teletherapy #mental health apps #behavioral health #therapist shortage #digital health platforms #psychiatric care

Transactions in connection with share buyback programme

GlobeNewswire Inc. • Netcompany Group A/S

Transactions in connection with share buyback programme

01/12/2026 07:56 AM • Netcompany Group A/S executed 66,000 share buybacks during the week of 5-9 January 2026 at an average price of DKK 361.99, bringing total accumulated buybacks to 1,443,896 shares worth DKK 411.1m. The company now holds 1,801,415 treasury shares (3.8% of share capital) following the transactions and vesting of restricted share units. The buyback programme, initiated on 14 August 2025 with a budget of DKK 500m and maximum 3.7m shares, will conclude by 30 January 2026.

NETGY - The share buyback programme is a routine capital management activity executed in compliance with regulations. The consistent execution of buybacks at stable prices (DKK 351-367 range) and progress toward programme targets indicates orderly, planned financial management. No material business developments or concerns are indicated, making this a neutral operational announcement.

#share buyback #treasury shares #capital structure #share-based incentive programmes #Market Abuse Regulation #Nasdaq Copenhagen

Global Catheters Market Size to Hit USD 55.58 Billion by 2033, Driven by Rising Cardiovascular and Urological Procedures – SNS Insider

GlobeNewswire Inc. • Sns Insider

Global Catheters Market Size to Hit USD 55.58 Billion by 2033, Driven by Rising Cardiovascular and Urological Procedures – SNS Insider

01/12/2026 07:52 AM • The global catheters market is projected to grow from USD 29.17 billion in 2025 to USD 55.58 billion by 2033, with a CAGR of 8.41%. Growth is driven by increasing cardiovascular and urological procedures, aging populations, and technological advancements. However, catheter-associated infections and antibiotic resistance pose challenges. North America dominates with 38.05% market share, while Asia Pacific is the fastest-growing region at 9.23% CAGR.

CPB - Stock down 26% in 2025, but shows potential bullish reversal with analyst price target suggesting upside
MDT - Company is advancing its APOLLO trial for the Intrepid TMVR device with over 2,500 patient enrollments, demonstrating active innovation and market expansion in transcatheter mitral valve replacement therapy.

#catheters market #cardiovascular procedures #urological procedures #minimally invasive procedures #medical devices #healthcare infrastructure #catheter-associated infections #antimicrobial coatings #silicone catheters #homecare settings

Biomedical and ICT Convergence Market Research Report 2025-2030: Opportunities in Developing Connected Medical Devices, Enhancing Precision Medicine, and Improving Healthcare Delivery

GlobeNewswire Inc. • Researchandmarkets.Com

Biomedical and ICT Convergence Market Research Report 2025-2030: Opportunities in Developing Connected Medical Devices, Enhancing Precision Medicine, and Improving Healthcare Delivery

01/12/2026 07:50 AM • A comprehensive market research report analyzing the convergence of Information and Communications Technology (ICT) and biomedical sciences through 2030. The report highlights opportunities in connected medical devices, precision medicine, and healthcare delivery optimization, driven by the need to address rising healthcare costs while improving patient outcomes through real-time monitoring and data-driven personalized treatments.

GIS - Strong baking season potential, parent of iconic brands like Pillsbury, trading at attractive 10x earnings with analyst price target indicating significant upside
ABT - Listed as a key company in the biomedical and ICT convergence market, positioned to benefit from growing demand for connected medical devices and diagnostic solutions.

#biomedical technology #ICT convergence #connected medical devices #precision medicine #healthcare delivery #IoT healthcare #wearable devices #telemedicine #personalized treatment #healthcare economics

Rumble Secures Exclusive Video and Live Streaming Rights for The Dan Bongino Show

GlobeNewswire Inc. • Not Specified

Rumble Secures Exclusive Video and Live Streaming Rights for The Dan Bongino Show

01/12/2026 07:47 AM • Rumble Inc. has secured an exclusive video and live streaming distribution agreement with The Dan Bongino Show, which will relaunch on February 2, 2026. The show will stream weekdays for two hours on Rumble exclusively, with audio versions available on major podcast platforms. Westwood One will handle advertising sales for the program.

MKC - Strongest revenue quarter historically, stable dividend with 38-year increase streak, attractive valuation with potential 21% upside
RUM - Rumble secured an exclusive high-profile content deal with a major media personality, strengthening its platform's content library and competitive positioning. The CEO highlighted this as marking 'a new era' for the platform ahead of the 2026 midterms, indicating strategic growth and increased user engagement potential.

#Rumble Inc. #Dan Bongino Show #exclusive distribution agreement #video streaming #podcasting #Westwood One #independent media

Valuation Implications of Domestic Rare Earth Supply Chain Reshoring Corporate Analysis Report 2025: MP Materials and Lynas Positioned for Growth Via Governmental Backing and Strategic Offtake Agreements

GlobeNewswire Inc. • Researchandmarkets.Com

Valuation Implications of Domestic Rare Earth Supply Chain Reshoring Corporate Analysis Report 2025: MP Materials and Lynas Positioned for Growth Via Governmental Backing and Strategic Offtake Agreements

01/12/2026 07:46 AM • A new market analysis report examines opportunities in reshoring rare earth supply chains to reduce Western dependency on China, which controls 85-90% of global refined production. The report identifies MP Materials and Lynas as key beneficiaries positioned for growth through government backing and strategic offtake agreements, with domestic suppliers potentially commanding 250-350% price premiums over Chinese benchmarks due to security considerations.

MKC.V - Strongest revenue quarter historically, stable dividend with 38-year increase streak, attractive valuation with potential 21% upside
MP - Identified as the leading U.S. rare earth producer with the only fully integrated U.S. mine-to-magnet operation at Mountain Pass. Positioned as a primary beneficiary of government backing, strategic offtake agreements with major customers (GM, Apple), and security premium valuations.

#rare earth elements #supply chain reshoring #geopolitical risk #domestic production #national security #China dependency #critical minerals #defense technology #green energy transition

First Watch Restaurant Group, Inc. Reports Preliminary Operational Metrics for the Fourth Quarter and Fiscal Year 2025

GlobeNewswire Inc. • First Watch Restaurant Group, Inc.

First Watch Restaurant Group, Inc. Reports Preliminary Operational Metrics for the Fourth Quarter and Fiscal Year 2025

01/12/2026 07:00 AM • First Watch reported strong 2025 performance with 64 new restaurant openings across 23 states, same-restaurant sales growth of +3.6%, and positive same-restaurant traffic growth of +0.5%. The company ended the year with 633 system-wide restaurants across 32 states and expressed confidence in its long-term strategy and 2026 pipeline.

FWRG - The company demonstrated strong operational performance with record 64 new restaurant openings in 2025, positive same-restaurant sales growth of +3.6%, positive same-restaurant traffic growth of +0.5%, and a strong pipeline for 2026. New restaurant classes are outperforming expectations and the comparable restaurant base, indicating healthy business momentum and successful execution of growth strategy.

#restaurant expansion #same-restaurant sales growth #daytime dining #new openings #operational metrics #franchise growth #traffic growth

RAD Increases Ownership in Radiopharm Ventures to 87.5%

GlobeNewswire Inc. • Not Specified

RAD Increases Ownership in Radiopharm Ventures to 87.5%

01/12/2026 07:00 AM • Radiopharm Theranostics increased its ownership stake in Radiopharm Ventures (joint venture with MD Anderson Cancer Center) from 75% to 87.5%. The leading candidate Betabart, a B7H3-targeting monoclonal antibody, received FDA IND clearance and is expected to dose the first patient in Q1 2026 in a Phase I trial for solid tumors. Two additional preclinical assets show early positive results with final candidate selection planned for 2026.

SHOP - Mentioned in context of beta-testing Managed Markets flow without detailed performance information
RADX - Company increased ownership stake in promising joint venture, lead candidate received FDA IND clearance, first-in-human trial expected to begin Q1 2026, and additional preclinical candidates showing positive results. These developments indicate strong pipeline progress and confidence in the program's potential.

#radiopharmaceuticals #oncology #B7H3 #Betabart #monoclonal antibody #Phase I trial #FDA IND clearance #joint venture #MD Anderson Cancer Center #solid tumors

Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy

GlobeNewswire Inc. • Na

Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy

01/12/2026 07:00 AM • Lexeo Therapeutics reported positive interim Phase I/II data for LX2020, an AAV-based gene therapy for PKP2-associated arrhythmogenic cardiomyopathy. The therapy demonstrated good tolerability across 10 participants, with 93-162% increases in PKP2 protein expression and stabilization or improvement in arrhythmia burden in the majority of participants. The company plans to complete 12-month data collection by Q4 2026 and engage with regulators in 2026.

TPR - Noted as a new partner in UK and Europe without specific performance context
LXEO - The company announced positive interim clinical trial data showing good safety profile, robust transduction, meaningful increases in PKP2 protein expression (93-162%), and clinically meaningful improvement or stabilization in arrhythmia burden across the majority of participants. No serious safety concerns were reported, and the therapy addresses an unmet medical need in a rare disease affecting approximately 60,000 people in the US.

#gene therapy #AAV #arrhythmogenic cardiomyopathy #PKP2 #Phase I/II trial #cardiac disease #protein expression #clinical trial data

Amplify ETFs Nominated for ETF Provider of the Year

GlobeNewswire Inc. • Na

Amplify ETFs Nominated for ETF Provider of the Year

01/12/2026 07:00 AM • Amplify ETFs announced four nominations across three categories in the With Intelligence Mutual Fund and ETF Awards, including ETF Provider of the Year. The company's blockchain, junior silver miners, and growth & income ETFs were recognized for their performance and innovation. Winners will be announced on February 11, 2026.

BLOK - BLOK received a nomination for Alternative ETF of the Year and holds a 5-star Morningstar rating. The fund demonstrated exceptional performance with 32.95% YTD return and 269.59% return since inception, positioning it as an early leader in blockchain investment exposure.

#ETF awards #Amplify ETFs #blockchain ETF #silver miners ETF #covered call options #asset management #investment performance

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire Inc. • Apellis Pharmaceuticals, Inc.

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

01/12/2026 07:00 AM • Apellis Pharmaceuticals reported preliminary full-year 2025 U.S. net product revenues of $689 million, driven by strong performance from SYFOVRE (geographic atrophy treatment) at $587 million and EMPAVELI (kidney disease treatment) at $102 million. SYFOVRE achieved 60% market share with 17% year-over-year injection growth, while EMPAVELI reached over 5% market penetration in its target indications within five months of launch. The company maintains approximately $466 million in cash and expects to reach profitability through product revenues.

DIS - Mentioned as a recipient of Chinese bank credit lines without specific negative or positive implications
APLS - Strong commercial execution with $689M in 2025 revenues, SYFOVRE achieving 60% market leadership with 17% YoY growth, EMPAVELI exceeding 5% market penetration in just 5 months post-launch, rapid payer uptake at 95%, positive Phase 3 data published in NEJM, pipeline expansion into additional indications (FSGS, DGF), and sufficient cash position ($466M) to fund operations to profitability.

#SYFOVRE #EMPAVELI #geographic atrophy #C3G #IC-MPGN #complement inhibitor #clinical trial #FDA approval #revenue growth #market penetration

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025

GlobeNewswire Inc. • Na

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025

01/12/2026 07:00 AM • Axogen reported preliminary full-year 2025 revenue of approximately $225.2 million, representing 20.2% growth over 2024, with Q4 2025 revenue expected at $59.9 million (21.3% increase). The company achieved FDA Biologics License Application approval for Avance® on December 3, 2025, and expects gross margins above 74%. Cash position improved by approximately $6.0 million to $45.5 million by year-end 2025.

QCOM - Mentioned as a recipient of Chinese bank credit lines without specific negative or positive implications
AXGN - Strong revenue growth of 20.2% year-over-year, significant FDA BLA approval milestone for Avance®, improved cash position, gross margins above 74%, and positive momentum across business functions support confidence in strategic execution and future growth prospects.

#peripheral nerve repair #FDA approval #BLA #revenue growth #Avance® #gross margin #commercial strategy #medical devices

Gaming and Leisure Properties, Inc. Schedules Fourth Quarter 2025 Earnings Release and Conference Call

GlobeNewswire Inc. • Na

Gaming and Leisure Properties, Inc. Schedules Fourth Quarter 2025 Earnings Release and Conference Call

01/12/2026 07:00 AM • Gaming and Leisure Properties, Inc. (NASDAQ: GLPI) announced it will release its 2025 fourth quarter financial results on February 19, 2026, followed by a conference call on February 20, 2026, where Chairman and CEO Peter M. Carlino and senior management will review quarterly results and performance.

BApA - Mentioned as a recipient of Chinese bank credit lines without specific negative or positive implications
GLPI - The article is a routine announcement of earnings release and conference call scheduling. It contains no information about financial performance, business developments, or market conditions that would indicate positive or negative sentiment. It is purely procedural in nature.

#earnings release #fourth quarter 2025 #conference call #financial results #real estate #gaming operators #triple-net lease

Five Below, Inc. Announces Holiday Sales Results for Quarter-To-Date Through January 3, 2026

GlobeNewswire Inc. • Na

Five Below, Inc. Announces Holiday Sales Results for Quarter-To-Date Through January 3, 2026

01/12/2026 07:00 AM • Five Below announced strong holiday period results with net sales increasing 23.2% to $1.47 billion and comparable sales growth of 14.5%. Based on this performance, the company raised its full year fiscal 2025 outlook, projecting net sales of approximately $4.75 billion with comparable sales increase of 12.5% and adjusted diluted EPS of $6.30 to $6.35.

BA - Mentioned as a recipient of Chinese bank credit lines without specific negative or positive implications
FIVE - The company exceeded expectations with strong holiday sales growth of 23.2%, solid comparable sales increase of 14.5%, and proactively raised full year guidance. CEO commentary highlights successful strategy execution, strong team performance, and confidence in 2026 opportunities. The company demonstrated broad-based results and improved customer journey initiatives.

#holiday sales #comparable sales growth #earnings outlook #retail performance #customer experience #inventory management #tariffs